A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Subjects With Varying Degrees of Renal Function

The purpose of this study is to investigate experimental medication BMS-986231 in patients with different levels of kidney function.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Body weight ≥ 45 kg and ≤ 120 kg
• BMI ≥ 18 kg/m^2 and ≤ 35 kg/m^2
• Heart rate ≥ 50 bpm and < 95 bpm
• Stable renal impairment, defined as no clinically significant change in disease status, as documented by the subject's most recent eGFR assessment
• No changes in medication within 30 days prior to study drug administration

Exclusion Criteria:

• Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests
• History of chronic headaches, defined as occurring 15 days or more a month, over the previous 3 months
• History of headaches related to caffeine withdrawal
• History of migraine or cluster headaches
• Patients requiring dialysis will not be enrolled in this study

Other protocol defined inclusion/exclusion criteria could apply